Structure Therapeutics (Structure Therapeutics) Change In Receivables : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Structure Therapeutics Change In Receivables?

Structure Therapeutics's change in receivables for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Structure Therapeutics's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Structure Therapeutics's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Structure Therapeutics's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Structure Therapeutics's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Structure Therapeutics's liquidation value for the three months ended in Mar. 2024 was $409.04 Mil.

Structure Therapeutics Change In Receivables Historical Data

The historical data trend for Structure Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Structure Therapeutics Change In Receivables Chart

Structure Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Structure Therapeutics Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial							-	-	-	-	-

Structure Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Structure Therapeutics (NAS:GPCR) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Structure Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Structure Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Structure Therapeutics's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	436.449	-	27.407	+	0.75 * 0	+	0.5 * 0
=	409.04

Structure Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Structure Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Structure Therapeutics (Structure Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Structure Therapeutics Inc (NAS:GPCR) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

611 Gateway Boulevard, Suite 223, South San Francisco, CA, USA, 94080

Website

https://www.structuretx.com

Structure Therapeutics Inc is a clinical-stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.

Executives

Ted W Love	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Trading Fund Os Lp	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners Os Ltd.	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Gp Holdings Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Melita Sun Jung	officer: Chief Business Officer	C/O STRUCTURE THERAPEUTICS INC., SOUTH SAN FRANCISCO CA 94080
Yingli Ma	officer: Chief Technology Officer	C/O STRUCTURE THERAPEUTICS INC., 611 GATEWAY BLVD., SUITE 223, SOUTH SAN FRANCISCO CA 94080
Joanne Waldstreicher	director	C/O STRUCTURE THERAPEUTICS INC., 611 GATEWAY BLVD, SUITE 223, SOUTH SAN FRANCISCO CA 94080
Jun Yoon	officer: Chief Financial Officer	C/O STRUCTURE THERAPEUTICS INC., 611 GATEWAY BLVD, SUITE 223, SOUTH SAN FRANCISCO CA 94080